
IBRX • NASDAQ
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold IBRX in your mock portfolio yet.
ImmunityBio is currently unprofitable, as indicated by its negative EPS of -0.41 and a negative PE ratio of -20.83. This suggests the company is still in an investment and development phase, relying on future growth expectations rather than current earnings. Without positive net income or profitability ratios, the financial profile remains high risk and highly dependent on successful execution of its pipeline and strategy.
The stock is trading at $8.54, up 16.3% over the last month, indicating recent positive momentum. The price is significantly above the 200-day moving average of $2.87, signaling a strong longer-term uptrend, while an RSI of 46.91 suggests the stock is neither overbought nor oversold. Overall, technicals lean bullish but also imply the potential for volatility given how far the price has run above its long-term average.
Alternative data points show improving engagement and growth signals around ImmunityBio. Website traffic of roughly 82,825 visitors per month, combined with rising social media followings across Twitter/X, Facebook, and LinkedIn, suggests increasing awareness and interest. The 6.7% month-over-month increase in job openings indicates ongoing investment in growth and operations, which is typically a positive forward-looking indicator if managed prudently.
ImmunityBio shows strong positive technical momentum and encouraging alternative data signals, but its lack of profitability and negative earnings keep the fundamental picture risky. The stock’s sharp move above its 200-day moving average and growing digital footprint suggest optimism and potential upside, yet this is built on expectations rather than established earnings power. Overall, the balance of strong sentiment and technicals against weak current financials supports a neutral stance with elevated risk and volatility.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
IBRX has experienced a significant price change of 41.9% over the last day, which is likely contributing to heightened activity among retail investors. Additionally, the volume is 2.9 times the average, consistent with increased trading activity, while there have been 23 mentions on Reddit in the past 24 hours, although this reflects a 9% decrease compared to the 7-day average.
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: